Now On Demand | Hosted by AAPS Small molecule biomarkers represent dynamic indicators of adverse effects in the setting of drug exposure and can provide an early warning of drug toxicity prior to histopathological changes. Nontargeted measurement of small molecule biomarkers in preclinical samples can lead to the discovery of early biomarkers that are associated with late-stage… Continue reading Timing is Everything: Biomarkers for Early Detection of Preclinical Toxicology Events
Now On Demand | Hosted by Oxford Global Advances in mass spectrometry resolution and sensitivity have enabled increasingly comprehensive views into the multitude of small molecule metabolites circulating in humans. These metabolites read out diverse host and environmental exposures that influence human health and may serve as critical biomarkers for driving early disease diagnostics, precision medicine approaches,… Continue reading High-Throughput Biomarker Discovery for Clinical Trial Optimization
There is increasing evidence of the human gut microbiome’s link to health and disease. Exploring the composition and function of these microbial communities can help us better understand the effects of microbiota perturbation on disease development and disease treatment. Due to the high sequencing and computational expense of whole-genome shotgun sequencing (WGS), most microbiome research… Continue reading Reconstructing the landscape of gut microbial species across 29,000 diverse individuals
If you look at the data, the best drugs work in only 50% of people. Sapient’s Founder and CEO, Dr. Mo Jain, sits down with Kelly Stanton, Director of Quality at Qualio, to explain this fundamental challenge and how it ultimately led to the creation of Sapient. There are thousands of biomarkers in our bloodstream that can… Continue reading “Lab to Launch” Podcast: Enabling the next generation of biomarker discovery with Dr. Mo Jain
Adaptive clinical trial designs seek to add flexibility to the fixed, linear “design-conduct-analyze” sequence of conventional clinic trials. Instead of assessing results after the trial is completed, adaptive designs allow for interim data reviews so that adjustments can be made during the study if warranted. From refining sample size to adjusting dosing regimens, pre-defined trial components can be modified based… Continue reading The Right Treatment, the Right Time: Biomarker-Guided Assessment of Clinical Trial Dynamics
Technology Networks’ Anna MacDonald sat down with Sapient’s Dr. Mo Jain for this Industry Insights piece to discuss the importance of improving biomarker discovery and how next-generation mass spectrometry (MS)-based systems can help to fill the current gap in biomarker technologies. Read an excerpt from the full feature below. Biomarkers can provide invaluable insight into our understanding of human disease, and may… Continue reading Technology Networks Feature: “Probing the Biomarker Landscape of Human Disease”
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. Small molecule biomarkers provide the next layer of biological insight to help complete the picture of human health and disease that genetics and proteomics have formed to date. Sapient’s Dr. Tanya Nguyen,… Continue reading Experts On… Delivering Value to Biopharma Sponsors
Biocompare recently spoke to a panel of experts, including Sapient’s CEO and Founder, Dr. Mo Jain, to get their takes on the challenges and opportunities of using mass spectrometry for biomarker discovery and research. Dr. Jain shares his perspectives on how technological advances in mass spectrometry are “releasing the brakes” that have constrained analytical speed… Continue reading Sapient Featured in Biocompare Article, “Mass Spectrometry for Biomarker Discovery”
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. Advancing precision medicine requires better understanding not only of how one patient differs from another, but also the factors that cause diseases and drug responses to differ. These differences can be caused… Continue reading Experts On… The Impact of Chemical Discovery at Scale
Now On Demand | Hosted by AAPS Will a patient respond or not respond to the given therapy? That is the fundamental question for any clinical trial – and not an easy answer to predict. Patients are unique; diseases are dynamic and represent heterogeneous biology, collectively leading to varied drug response. Aligning patients, disease biology, and therapeutic… Continue reading The Clinical Trial Conundrum: Identifying Responders vs. Non-Responders
10421 Wateridge Circle, Suite 100
San Diego, CA 92121
discover@sapient.bio
858.290.7010
© 2024 Sapient Bioanalytics, LLC. All rights reserved.
SAPIENT, the SAPIENT Logo, ACCELERATE HUMAN DISCOVERY, and SPECIFICITY AT SCALE are trademarks of Sapient Bioanalytics, LLC
